

Discover Top Biotechnology Partners from Poland

Business Catalogue

save
the date for
#CEBioForum2024
26-27 March

Warsaw

next edition

Visit Poland and discover the potential of #polishbiotech and other Central European countries during CEBioForum conference - the best spot to find your business partner.

More details: @ www.cebioforum.com
in Central European BioForum



Polish Biotechnology Sector

COMPANY NAME: The Association of Biotechnology Companies BioForum
WEBSITE : <https://www.bioforum.pl>
YEAR OF ESTABLISHMENT: 2000
NUMBER OF EMPLOYEES: 5
CERTIFICATIONS: not applicable



PRODUCTS: CEBioForum - networking conference for biotech companies where you can meet entrepreneurs from whole Europe in one spot, where you can discover growing potential of local business & science

FORM OF COOPERATION: Trade and distribution, Joint Venture, Investment



Association of Biotech Companies BioForum in Poland plays a vital role in promoting the biotechnology sector, fostering collaboration, providing support, and representing the interests of its members. BioForum serves as a platform for collaboration and communication among biotech companies, research institutions, government agencies, and other stakeholders involved in the field. During CEBioForum conference we are connecting companies, researchers, and entrepreneurs and we encourage partnerships and synergies that can lead to innovative developments and advancements in biotechnology. Moreover, we represent biotech sector internationally and in front of governmental agencies.



BioInMed has 19 members - Polish innovative medical biotech and biopharma companies.

Their projects address unmet medical needs. They concern various technologies: small molecule and biological drugs, as well as ATMP, including cell or gene therapies, stem cells, nucleic acid-based therapies and others. In Poland, we conduct a broad spectrum of R&D projects in different therapeutic areas: oncology, neurology, psychiatry, diabetology, pulmonology and many others. Polish companies are working on unique, innovative technologies on cross-border scale. The most mature projects are already in phase 2 of clinical trials.

BioInMed i.a. establishes international relations, promoting the achievements of the Polish medical biotech on international arena to substantive, business and investment partners.

We look forward to working with you!

Polish Biotechnology Sector

COMPANY NAME: Polish Union of Innovative Medical Biotech Companies BioInMed

WEBSITE : <https://www.bioinmed.pl/en>

YEAR OF ESTABLISHMENT: 2021

NUMBER OF EMPLOYEES:

CERTIFICATIONS:



PRODUCTS: Industry organisation supporting Polish medical biotech and biopharma industry

FORM OF COOPERATION: Investment



Polish Union of Innovative Medical Biotech Companies BioInMed is an industry organization associating Polish medical biotechnology companies that conduct R&D projects in the field of drug discovery and drug development (first and better in class), diagnostic methods based on biotechnology. BioInMed companies also provide tools that support research and development processes, including AI, machine learning, genom diagnostics or platform technology to directly label DNA lesions at an individual level.

Polish Biotechnology Sector

COMPANY NAME: A4BEE

WEBSITE : <https://www.a4bee.com/>

YEAR OF ESTABLISHMENT: 2018


NUMBER OF EMPLOYEES: 130

CERTIFICATIONS: EcoVadis Sustainability Rating



PRODUCTS: Connectivity & Integration; End-2-end software & platform development; Cloud bioprocess monitoring; AR/VR solutions; Lab retrofitting; edge and IoT connectivity; Control and Automation engineering; Modular biotech smart components; Security and Compliance Auditing & Testing; Lab & manufacturing equipment UX/UI

FORM OF COOPERATION: Trade and distribution



A4BEE accelerates, connects, and simplifies pharma and biotech processes. We provide end-2-end services like digital advisory, software & platform development, AR/VR solutions, data acquisition, and IoT hardware. Our 130-person team of engineers, developers, biotechnologists, and consultants, empowers global players at every stage of their digital transformation journey while solving real-world problems. We support companies across the globe - USA, UK, Denmark, Poland, Germany, France, Singapore, and India.

Polish Biotechnology Sector

COMPANY NAME: Adamed Pharma S.A.

WEBSITE : <https://www.adamed.com/en/main-page>

YEAR OF ESTABLISHMENT: 1986

NUMBER OF EMPLOYEES: 2700

CERTIFICATIONS: GMP; GMP EAEU; GDP API



PRODUCTS: Adamed provides patients with the highest quality medicinal products across 19 therapeutic areas. The company's intellectual property is protected by over 200 patents, and its portfolio includes over 500 products, such as: prescription drugs, OTC drugs, dietary supplements, dermocosmetics, medical devices.

FORM OF COOPERATION: Trade and distribution, Joint Venture, Investment



Adamed Pharma is a Polish research- and patent-based pharmaceutical and biotechnology company. In 2023 it employs almost 2700 people and owns 3 production plants. Adamed drug discovery team has deep R&D experience with apoptosis pathways in cancer science. Currently two company's assets: AD-O21.32 and AD-O51.4 are on the pre-IND stage with plan for the FIH studies in 2024. Another TRAIL/Apo2 based drug candidates are prepared to the ADME/PK and tox studies. The second therapeutic area with strong expertise is a mental disorders treatment accompanied by a deep knowledge in multimodal ligands development. In 2021 Adamed signed the worldwide license agreement with Acadia Pharmaceuticals.

COMPANY NAME: Ardigen



WEBSITE : <https://www.ardigen.com>


YEAR OF ESTABLISHMENT: 2015

NUMBER OF EMPLOYEES: 230

CERTIFICATIONS: ISO 27001, Great Place to Work

PRODUCTS: Artificial Intelligence and Bioinformatics services for Drug Development and Precision Medicine, AI CRO in the fields of Target ID, Hit to Lead, Phenotypic Screening, Small Molecules, Neoantigens, TCRs, Antibodies, Microbiome, Multiomics, Single Cell, Computer Vision, GPT Models, Machine Learning, Data Engineering.

FORM OF COOPERATION: Trade and distribution



Ardigen, AI CRO company, enables AI transformation for biotech and pharmaceutical companies to leverage the full potential of data. The company delivers value at the intersection of biology and computational methods to increase the likelihood of success and accelerate the drug discovery process. With our platforms based on advanced algorithms and state-of-the-art technology, we help researchers to get scientific insights from a large amount of data, leading to new discoveries and breakthroughs in fields such as personalized medicine and drug development.

COMPANY NAME: Auxilius Pharma



WEBSITE : <https://www.auxiliuspharma.com>

YEAR OF ESTABLISHMENT: 2019

NUMBER OF EMPLOYEES: 8

CERTIFICATIONS: Auxilius Pharma has implemented Quality Management System to be fully compliant with GCP, GMP and GLP standards.

PRODUCTS: Auxilius Pharma is developing a new once-daily, first line agent for Chronic Stable Angina Pectoris, a disease affecting 3-4% of the population. The product has been in use in the EU but not yet approved in the US. Auxilius Pharma has reformulated it into a once daily to add value to patients by improving the quality of control of the underlying condition.

FORM OF COOPERATION: Investment

Our mission is to to improve the lives of our patients by offering them access to effective and verified pharmaceutical treatments in convenient dosage form. We are developing a unique portfolio of value-added reformulated product candidates by utilizing expertise and technological advancements in drug formulation and manufacturing. Our development approach makes use of the 505(b)(2) regulatory pathway in the US. This pathway has been created for pharmaceuticals for which the safety and efficacy have previously been demonstrated. This targeted approach can considerably cut the amount of clinical work necessary to get a product to market, shorten the development cycle, and lower costs and risk.

COMPANY NAME: Captor Therapeutics S.A.



WEBSITE : <https://www.captortherapeutics.com/>

YEAR OF ESTABLISHMENT: 2018

NUMBER OF EMPLOYEES: 110

CERTIFICATIONS:

PRODUCTS: Captor uses Targeted Protein Degradation to develop drugs for severe diseases with no satisfactory treatments. Captor aims to treat oncological and autoimmune diseases with class leading drugs that remove disease-causing proteins beyond the reach of traditional drugs, and plans two drugs in clinical trials by 2024.

FORM OF COOPERATION: Investment



At BIO, Captor is interested in meeting with major pharmaceutical biotechnology companies with an interest in in-licensing development candidates, or in establishing new drug discovery collaborations against targets of interest. In addition, Captor has developed new approaches to Targeted Protein Degradation with potential applications in new areas, such as degrader payloads for Antibody Drug Conjugates, and exploiting novel E3 Ligases to develop next generation degrader drugs. In addition to partnerships with pharma, Captor is also interested in meeting with international financial institutions and investors who could assist us in our strategy of global growth.

COMPANY NAME: Celon Pharma S.A.



WEBSITE : <https://www.celonpharma.com>

YEAR OF ESTABLISHMENT: 2002

NUMBER OF EMPLOYEES: 520

CERTIFICATIONS: GMP, GLP.

PRODUCTS: Branded generics portfolio: Salmex, Ketrel, Donepex, Valzek Innovative projects portfolio: 5 clinical stage assets and multiple identified leads targeting large market opportunities in neuropsychiatry, oncology, metabolism & inflammation.

FORM OF COOPERATION: Joint Venture, Investment



We are actively seeking opportunities to partner in terms of our clinical and preclinical programs by acquisition, in-licensing, or co-development. Our unique hybrid business model combining positive cash flows and integrated pharma experience with a diversified pipeline of highly innovative programs. Broad pipeline of 5 clinical stage assets and multiple identified leads targeting large market opportunities in neuropsychiatry, oncology, metabolism & inflammation - potential blockbusters with wholly owned IP. Advanced early-stage pipeline: 8 innovative programs in pre-clinical.

Polish Biotechnology Sector

COMPANY NAME: ExecMind. Life Science Executive Search

WEBSITE : <https://www.execmind.com>

YEAR OF ESTABLISHMENT: 2015


NUMBER OF EMPLOYEES: 4

CERTIFICATIONS: -



PRODUCTS: C-level and senior management executive search for Life Science, Biotechnology and Medical Technologies companies; Scientific Talents Acquisition; recruitment of international Business Development senior and commercial roles; support in building Scientific Advisory Boards; www.BioTechVibes.com – Life Sciences job board

FORM OF COOPERATION: Trade and distribution



ExecMind is an executive search company connecting life sciences companies with world-class scientists and visionary leaders. We support biotechnology, pharma, medical devices, clinical research organizations, and venture/private investment funds. We collaborate with international big pharma, mid-size companies, and start-ups, offering the best candidates for the job and handling the executive search, interim management, and other processes that support business growth. ExecMind attracts experienced talents worldwide who can deliver high-quality contributions to our clients and share their vision and values.

Polish Biotechnology Sector

COMPANY NAME: ExPLoRNA Therapeutics

WEBSITE : <https://www.explorna.com>

YEAR OF ESTABLISHMENT: 2019


NUMBER OF EMPLOYEES: 28

CERTIFICATIONS: -



PRODUCTS: 5' mRNA cap analogs: AvantCap, ExploCap & more which offer unique advantages when used for immunization or for therapeutic protein delivery by increasing the effectiveness of mRNA medicines, reducing their necessary doses, and saving costs.

FORM OF COOPERATION: Trade and distribution



ExPLoRNA Therapeutics is a biotech start-up focused on mRNA technology, bringing 20+ years of experience in research and innovation into novel therapeutics and vaccines. The 5' mRNA cap analogs invented by the company founders have been recognized for its potential by multiple partners in the US, Europe and in Asia. We deliver our patented compounds to biotech and pharma partners seeking enabling technologies, quality, and process improvements for the next generation of mRNA vaccines and therapeutics.

Polish Biotechnology Sector

COMPANY NAME: Genomtec S.A.



WEBSITE : <https://www.genomtec.com>

YEAR OF ESTABLISHMENT: 2016

NUMBER OF EMPLOYEES: 20

CERTIFICATIONS: The company has EU CE-IVD certification for the Genomtec ID RP5-PLEX diagnostic panel and ISO 13485.

PRODUCTS:

1. Genomtec ID: Point-of-care Molecular testing Analyzer
2. Genomtec ID RP 5-Plex: A microfluidic lab-on-a-chip technology that rapidly identifies most common respiratory pathogens causing infectious diseases.

FORM OF COOPERATION: Trade and distribution, Joint Venture, Investment



Genomtec is a Molecular Diagnostics venture committed to introducing a fast mobile point of care testing platform with the aim to decentralize current laboratory testing practices. Company has ready to scale SNAAT isothermal technology. The company is looking for global partners interested in further developing the technology and its implementation in applications within infectious diseases or oncology based companion diagnostics. The Genomtec technology is protected by 10 patents granted in Europe, the USA and Japan, and over 20 patent pending applications in global markets.

Polish Biotechnology Sector

COMPANY NAME: genXone S.A.



WEBSITE : <https://www.genxone.eu>


YEAR OF ESTABLISHMENT: 2016

NUMBER OF EMPLOYEES: 24

CERTIFICATIONS: ISO 9001:2015, Oxford Nanopore Technologies Certification

PRODUCTS: Gut microbiome test NANOBIOME; Whole Genome Sequencing; Whole Plasmid Sequencing; Metagenomic Sequencing; 16S and/or ITS Gene Sequencing; Bioinformatics; Bespoke Analysis; SARS-CoV-2 genome Sequencing; Molecular diagnostics; Clinical Trials; Tick analysis;

FORM OF COOPERATION: Trade and distribution



genXone address their offer to: scientific sector (sequencing services for R&D projects, eg. WGS, 16s/ITS, whole plasmid sequencing, microbiomes of various environments), FMCG sector and epidemiological supervision (microbiological monitoring) and medicine (clinical trials, diagnostics, genetic disorder test). The main project is the NANOBIOME test based on sequencing of gut microbiome. genXone operates globally.

COMPANY NAME: Gyncentrum Sp. z o.o.



WEBSITE : <https://www.gynlab.pl>

YEAR OF ESTABLISHMENT: 2011

NUMBER OF EMPLOYEES: 606

CERTIFICATIONS: We have the following certificates: ISO9001 and ISO27001. We are in the process of certification in ISO 15189

PRODUCTS: Personalization of viral vectors of chimeric antigen receptors. We are working on a T cell modification protocol with the incorporation of chimeric antigen receptors in order to implement oncology therapy.

FORM OF COOPERATION: Trade and distribution, Joint Venture, Investment



The Gyncentrum Genetic Laboratory is one of the leading centers in Europe specializing in genetic diagnostics of infertility and miscarriages, preimplantation PGS-NGS diagnostics, oncogenetics, carriers of genetic diseases, pharmacogenetics, bacterial and viral infections. The clinic has been awarded six times in the "Highest Quality International" plebiscite under the patronage of the Polish Committee Standardization, PARP and universities. We have a Certificate of Information Security Management and Quality Management as well. We conduct clinical trials and we are an Accredited Training Center. Gyncentrum has 5 centers in Poland, and another 3 will be opened soon.

COMPANY NAME: Intelliseq



WEBSITE : <https://www.intelliseq.com/>


YEAR OF ESTABLISHMENT: 2014

NUMBER OF EMPLOYEES: 20

CERTIFICATIONS: ISO 13485

PRODUCTS: IntelliseqFlow automates the entire process of genetic data analysis and generates complete final reports dedicated to diagnosticians, genetic counselors and/or patients depending on the selected analytical workflow. In addition, we also offer solutions tailored to the individual needs of a given client.

FORM OF COOPERATION: Trade and distribution, Investment



Intelliseq operates at the intersection of healthcare and computational genomics, providing advanced bioinformatics solutions for genome-based medicine. Our mission is to enable a broader access to clinical interpretation of genomic data through automated, innovative tools for NGS data analysis and interpretation for diagnostics, treatment, and prevention. We offer ready-to-use bioinformatic workflows for PGx, Germline Disorders, Somatic Cancer, and Polygenic Risk Scoring all wrapped up into one platform, IntelliseqFlow. The system drives lab efficiency through streamlined raw DNA data-to-reporting flow. The platform is available either in a cloud-hosted or on-prem model.

COMPANY NAME: intoDNA



WEBSITE : <https://www.intodna.com/>

YEAR OF ESTABLISHMENT: 2017

NUMBER OF EMPLOYEES: 38

CERTIFICATIONS: -

PRODUCTS: intoDNA offers the end-to-end service of super-sensitive and direct DNA breaks detection based on STRIDE, intoDNA's proprietary technology. STRIDE is a versatile method that enables selective single- or double-strand DNA breaks detection. New assays have been developed to detect DDR proteins in proximity of DNA breaks.

FORM OF COOPERATION: Trade and distribution



intoDNA is offering STRIDE-based proprietary services to small and mid-size biotechs, as well as big pharmaceutical companies globally. We operate as a full-service DNA quality assessment lab offering experimental design and optimization, a wide range of staining and co-staining options, quantitative 3D image analysis, and comprehensive results presentations. STRIDE brings value to early stage screening, efficacy and mechanistic studies, as well as translational and clinical research of anticancer drugs in the DDR, radiotherapeutic and immunotherapy fields as a pharmacodynamic biomarker.

COMPANY NAME: Jagiellońskie Centrum Innowacji



WEBSITE : <https://www.jci.pl>


YEAR OF ESTABLISHMENT: 2004

NUMBER OF EMPLOYEES: 150

CERTIFICATIONS: ISO9001; ISO13485:2016-04; implemented requirements ISO22716 & food safety management system based on HACCP; GMP

PRODUCTS: Commercial laboratory research outsourcing of research services R&D research quality control studies of medicinal products quality control studies (API) testing the biological activity of substances assessment of the antimicrobial activity of substances and products design and validation of analytical methods

FORM OF COOPERATION: Trade and distribution



The Jagiellonian Center of Innovation company was established in 2004 by the Jagiellonian University in Krakow with a view to developing and managing the infrastructure of the Life Science Park as well as providing a wide range of services to entrepreneurs and scientists engaged in life sciences sector. We operate in the following industries: pharmaceuticals, medical devices, clinical trials, cosmetics, food and dietary supplements. So far, we have cooperated with small and mid-size, as well as big companies from European countries and the USA.

Polish Biotechnology Sector

COMPANY NAME: JJP BIOLOGICS Sp. z o.o.

WEBSITE : <https://www.jjpbioletics.com>

YEAR OF ESTABLISHMENT: 2016


NUMBER OF EMPLOYEES: 20

CERTIFICATIONS: -



PRODUCTS: IMMUNOLOGY Anti-CD89 First-in-Class mAb targeting IgA. MoA: blocking neutrophil activation. Target: IgA-mediated inflammatory diseases. ODD - Linear IgA Bullous Dermatitis (LABD)
ONCOLOGY Anti-CD270 MoA: enhancing T cell function against tumors. Target: Melanoma, Colorectal cancer, Liver cancer, Esophageal Carcinoma

FORM OF COOPERATION: Trade and distribution, Joint Venture, Investment



Three-pillar strategy: Companion diagnostics, Molecular pathways, Smart PoC. Our competences:

- Experience in innovative biotechnological drugs development
- Team of experts – scientific, medical, laboratory and project management
- 4 candidates for advanced biological drugs in immunology and oncology
- Collaboration with research centers (Universities in Amsterdam, Gdansk, Warsaw Medical University, Erasmus University MC Rotterdam, Universitätsklinikum Schleswig-Holstein). JJP Biologics pursues development of its own product candidates as well as projects executed in cooperation with scientific partners. Development programs target general immune pathways in autoimmune diseases and cancer.

Polish Biotechnology Sector

COMPANY NAME: KAWA.SKA Sp. z o.o.

WEBSITE : <https://www.kawaska.pl>

YEAR OF ESTABLISHMENT: 1999


NUMBER OF EMPLOYEES: 40

CERTIFICATIONS: We dont have any



PRODUCTS: confocal microscopes; fluorescence microscopes; stereo microscopes; tissue processors, consumables for histology; cryostats; microtomes; staining systems; autopsy equipment; software solutions for digital pathology; mass spectrometers ; time-resolved fluorimetry products; automated systems for DNA and RNA isolation

FORM OF COOPERATION: Trade and distribution



KAWA.SKA is a company from Poland (Europe). We have been providing solutions for the biotechnology sector on the Polish market for 24 years. We operate in the sector of microscopy and laboratory solutions, our clients are: Universities, Medical Universities, Institutes belong to the Polish Academy of Science, departmental Institutes, hospitals and biological laboratories. Our product portfolio is focused on devices used in biology, molecular biology, biotechnology, environmental protection, molecular diagnostics, histopathology and autopsy. We are a distributor of innovative biotechnological solutions supplied by producers from Germany, Spain, Great Britain and the USA.

COMPANY NAME: Klaster Life Science Kraków

WEBSITE : <https://www.lifescience.pl>

YEAR OF ESTABLISHMENT: 2006

NUMBER OF EMPLOYEES: 7

CERTIFICATIONS: • National Key Cluster certificate; • The ECEI SILVER Label • Poland EIT Health Hub status

PRODUCTS: •LSOS Collaboration Platform, a multifunctional tool for the life science community, stimulating collaboration and resource sharing (<https://LifeScienceOpenSpace.com/>) •Life Science Open Space, an event for scientists, innovators, entrepreneurs, brokers, investors, officials – willing to cooperate (<https://lsos.info/>)

FORM OF COOPERATION: Trade and distribution, Investment



Klaster LifeScience Krakow is a cooperation network of partners from business, science, health and administration sectors, operating in the field of innovative products and technologies for Health and Quality of Life. Solutions offered include: •access to knowledge, information and special research resources; •networking and collaboration tools; •organizational, legal, marketing, financial, logistic and technological support; •creating strategic alliances including centers of excellence and project groups between enterprises and research centers at both regional and international levels; •support for the commercialization of research results.

COMPANY NAME: Leaderna

WEBSITE : <https://www.leaderna.com>


YEAR OF ESTABLISHMENT: 2015

NUMBER OF EMPLOYEES: 10

CERTIFICATIONS: Positive Information Security Assessment by The Prevalent Third-Party Risk Management Platform

PRODUCTS: Leaderna Platform Pharma/Biotech Project Management web tool available in cloud and on-premise;
Leaderna Biostructures biotech services: Gene preparation, Protein production, X-ray crystallography, Crystallographic Fragment Screening, Cryo-EM, Micro-ED, Biophysical and Biochemical analysis;

FORM OF COOPERATION: Trade and distribution, Joint Venture, Investment



LEADERNA's mission is to support Drug Discovery & Development projects for the treatment of serious diseases. Leaderna Biostructures has an established position in the field of Structure-Based Drug Design. Provides complete Gene-to-Structure service using X-ray crystallography and cryoEM methods. The results have supported the efforts of a number of companies, including pharmaceutical leaders, to discover drugs for diseases such as cancer, asthma, or IPF. Based on this experience, Leaderna Platform developed a specialized Project Management web tool for the pharma/biotech sector. Unique map-like approach reflects the logic of complex DD projects and organizes the use of resources or data collection.

COMPANY NAME: Mabion S.A.

MABION

WEBSITE : <https://www.mabion.eu/>

YEAR OF ESTABLISHMENT: 2007

NUMBER OF EMPLOYEES: 249

CERTIFICATIONS: • GMP Certificate • GLP Certificate • ISO 14001:2015 • ISO 45001:2018 • ISO 50001:2018

PRODUCTS: Mabion is a biologic CDMO providing multiple services related to biologic drug development and manufacturing: • Clinical and Commercial Manufacturing • Process Development • Pre-Clinical and Clinical Analytics • Drug Characterization and Release Testing • Fill & Finish • Regulatory and Consulting

FORM OF COOPERATION: CDMO Services



Mabion's offer is directed to a wide spectrum of biopharmaceutical companies seeking to outsource one or more elements of their development program and/or clinical or commercial manufacturing. Mabion was established as an R&D company developing biosimilars, but it has recently undergone a review of its business strategy and became a focused end-to-end biologics CDMO. The company has well equipped GMP- and GLP-certified facilities with a dedicated platform for biologics manufacturing. Mabion has extensive experience in almost all facets of biologic medication research and production thanks to the lengthy history of working on own products and contract manufacturing of COVID-19 vaccine antigens.

COMPANY NAME: MEDICOFARMA BIOTECH S.A.



WEBSITE : <https://www.medicofarmabiotech.pl>


YEAR OF ESTABLISHMENT: 2021

NUMBER OF EMPLOYEES: 23

CERTIFICATIONS: Good manufacturing practice (GMP)

PRODUCTS: Anticancer therapies based on RNA and low-molecular-weight compounds. Regenerative therapy based on low-molecular-weight compounds.

FORM OF COOPERATION: Joint Venture, Investment



We deliver innovative therapies that address the unmet clinical needs, especially patients suffering from severe cancer types, such as pancreatic cancer and glioblastoma (GBM). Our leading project - "Anti-cancer therapy based on RNA technology" is focused on GBM. Until now, we have developed and validated the efficacy and safety of three therapeutic candidates in the preclinical proof-of-concept studies. The compounds and formulations are protected by three pending patents. The Company is preparing to initiate the first-in-human clinical trial. Designed therapy is a first RNA-based alone or adjuvant therapy for the treatment of gliomas. We are a member of European Federation of Biotechnology.

COMPANY NAME: Molecule One Sp. z o.o.

WEBSITE : <https://www.molecule.one/>

YEAR OF ESTABLISHMENT: 2016

NUMBER OF EMPLOYEES: 23

CERTIFICATIONS: -



PRODUCTS: RetroM1 - retrosynthesis pathway planner; RetroSAS - Synthetic Accessibility Scoring tool; CouplingM1 - reaction conditions recommendation tool; High Throughput Laboratory Data; Custom Laboratory solutions;

FORM OF COOPERATION: Trade and distribution



Molecule.one is an AI-driven biotech company enhancing drug discovery with predictive chemistry systems. Using deep learning and data from our high-throughput chemistry laboratory, we create tools that simplify chemical synthesis planning. Our services boost chemist's efficiency with retrosynthesis prediction, reaction condition suggestions, and synthesis feasibility assessments of compound libraries. Our diverse team of chemistry, IT and machine learning experts ensures we consistently provide high-quality solutions to chemists worldwide.

COMPANY NAME: MOLECURE S.A.

WEBSITE : <https://www.molecure.com>

YEAR OF ESTABLISHMENT: 2012

NUMBER OF EMPLOYEES: 109

CERTIFICATIONS: -

molecure

PRODUCTS: Small molecules; Small molecules targeting mRNA ; First in class and best in class drugs; Chitinase inhibitors; Inflammatory fibrotic diseases; Sarcoidosis; Dual arginase inhibitors; Immuno-oncology; Deubiquitinase inhibitors; Phase 1 and phase 2 programs; Macrophages and T cell modifiers

FORM OF COOPERATION: Investment



Molecure is a clinical stage biotechnology company discovering and developing first-in-class small molecule drug candidates that directly modulate underexplored protein targets and the function of RNA to treat multiple incurable diseases. We have generated a diverse pipeline of 7 distinct programs with the support of leading academic life science institutions globally. Our most advanced in-house drug candidate is OATD-01, a Ph2 chitinase inhibitor for the treatment of sarcoidosis and other ILDs. OATD-02, our second proprietary candidate, is an oral, potent and selective dual arginase inhibitor (ARG1/2) in Ph1 for the treatment of cancer. We also explore DUBs and develop mRNA platform.

COMPANY NAME: Orphnic Scientific SA

WEBSITE : <https://www.orphnic.com/>

YEAR OF ESTABLISHMENT: 2019


NUMBER OF EMPLOYEES: 12

CERTIFICATIONS: Our plan is to IPO at Warsaw Stock Exchange by the end of 2023.



PRODUCTS: Orphnic currently has 10 projects in the pipeline - from a preclinical phase to market approval stages in three healthcare segments: therapeutics, medtech and e-health. Our portfolio represents clinic-ready assets, with first projects ready to exit in early 2024, and a preclinical pipeline for long-term value creation

FORM OF COOPERATION: Trade and distribution, Joint Venture, Investment



Orphnic Scientific S.A. - first Polish biotech portfolio platform creating innovative solutions for orphan diseases and other indications with significant unmet medical needs in the clinical trial phase. Orphnic core scientific team consist of experts with over 20 years experience in clinical development processes and their commercialization. The company's competencies in clinical stage development are further enforced through a collaboration with a large clinical CRO operating in the CEE region. This facilitates access to diverse patient populations and rapid enrollment to clinical trials supporting our projects and significantly shortens the duration of individual phases.

COMPANY NAME: Pikralida sp. z o.o.

WEBSITE : <https://www.pikralida.eu/en/>

YEAR OF ESTABLISHMENT: 2019

NUMBER OF EMPLOYEES: 22

CERTIFICATIONS: not applicable



PRODUCTS: Project EpiFix: We are targeting prevention of epilepsy development following traumatic brain injury or stroke. Initiation of phase I clinical trial is scheduled for H2 2023. Project ALS: We are running the scientific research project to identify the lead structures and a clinical candidate in the next few years.

FORM OF COOPERATION: Joint Venture, Investment



Pikralida is conducting scientific projects aimed at the discovery and development of breakthrough therapeutic solutions offering the response to unmet medical needs of patients. We carry out projects starting from the design of an innovative therapeutic solution up to clinical verification of the idea in the form of proof-of-concept clinical trials. Our portfolio covers the implementation of projects based on our original concepts, purchased licences, and based on the revolutionary discoveries of the academic science teams. We are looking for research collaborations and partnership with pharmaceutical companies that would advance clinical development of our lead project.

Polish Biotechnology Sector

COMPANY NAME: PioLigOn Sp. z o.o.

WEBSITE : <https://www.pioligon.pl/>





YEAR OF ESTABLISHMENT: 2020

NUMBER OF EMPLOYEES: 4

CERTIFICATIONS: in progress

PRODUCTS: VPDesigner42™ is an innovative platform for hit and lead discovery catering to the needs of customers in the pharmaceutical and biotechnology sectors.

FORM OF COOPERATION: Trade and distribution, Joint Venture, Investment



Our offer is targeted towards customers in the pharmaceutical and biotechnology sectors who are in need of drug prototypes, particularly for targeted cargo delivery, radiotherapeutics and hit discovery for protein-protein interactions. We have completed multiple proof of concept studies and are looking for new customers for our technology. VPDesigner42™ offers a novel approach to the discovery of therapeutic peptides and hit molecules. It combines in silico methods with complementary chemistry, allowing the use of an unlimited number of different amino acids in designed peptides. This approach sets VPDesigner42™ apart from other methods and enables unmatched speed in the discovery process.

Polish Biotechnology Sector

COMPANY NAME: POLSERVICE Patent and Trademark Attorneys Office

WEBSITE : <https://www.polservice.com.pl>

YEAR OF ESTABLISHMENT: 1964

NUMBER OF EMPLOYEES: 100

CERTIFICATIONS: PN-EN ISO/IEC 27001

PRODUCTS: Drafting and prosecution of patent, utility model, trademark and design applications in Poland, EU and abroad; Enforcement of IP rights; IP renewals; Recordal of changes in IP registers; Creating IP Protection Strategies; Protection of plant varieties; IP expert reports; Legal opinions; Patentability and FTO searches

FORM OF COOPERATION: Trade and distribution, Investment

POLSERVICE
PATENT AND TRADEMARK
ATTORNEYS OFFICE



POLSERVICE Patent and Trademark Attorneys Office is one of the leading intellectual property (IP) firms in Poland and Central Europe, operating since 1964 with a team of experts specialized in various technical and legal fields. POLSERVICE delivers full range of IP services at the national, international and EU/EPO levels, including prosecution of national, international and European patent, trademark and design applications, renewals of IP rights, validations of European Patents, counselling on licensing and enforcement of IP rights. POLSERVICE represents international corporations, domestic enterprises, universities, SMEs, start-ups, i.a. from biotech, life sciences and pharma sectors.

COMPANY NAME: Poltreg S.A.



WEBSITE : <https://poltreg.com/>

YEAR OF ESTABLISHMENT: 2016

NUMBER OF EMPLOYEES: 47

CERTIFICATIONS: GMP for ATMP (investigational and Hospital Exemption)

PRODUCTS: a. Polyclonal TREGs in clinical stage for T1D and MS b. CAR-TREG in pre-clinical stage for ALS and other neurodegenerative disease c. Antigen-specific TREG in pre-clinical stage for autoimmune diseases d. TCR-TREG – in R&D program Horizon Europe

FORM OF COOPERATION: Joint Venture, Investment



We look for pharma partner to develop TREG therapies to address autoimmune diseases. Poltreg offers autologous cell therapy with naturally occurring polyclonal Tregs expanded ex vivo. We completed phase II trial in symptomatic phase II T1D and phase I in MS. The next steps are pivotal trial in symptomatic T1D, phase I/II in presymptomatic T1D and phase II in MS (RRMS and PPMS). The new generation engineered Tregs, such as CAR-Tregs, TCR-Tregs and antigen-specific Tregs are in the preclinical stage. Poltreg has its own GMP facility for manufacturing with capacity of 50 preparations per month. The therapy has been offered commercially in a limited scale in Hospital Exemption mode.

COMPANY NAME: Pure Biologics S.A.



WEBSITE : <https://www.purebiologics.com/>

YEAR OF ESTABLISHMENT: 2010

NUMBER OF EMPLOYEES: 64

CERTIFICATIONS: -

PRODUCTS: Biological drug; Systemic therapies discovery and development

FORM OF COOPERATION: Joint Venture, Investment



Pure Biologics (Warsaw stock exchange: PUR) is a biopharmaceutical company focused on the development of biological drugs and systemic therapies for treatment of cancer and chronic inflammation. Pure Biologics has created two highly efficient drug-development platforms to generate therapeutic antibodies and modified aptamers, supported by state-of-the-art assays and analytics. Pure Biologics is on the market since 2010, with headquarters and laboratories located in Wrocław, Poland. Pure Biologics employs over 60 people, and has a broad portfolio. Pure Biologics is one of Poland's largest biotechnology companies.

Polish Biotechnology Sector

COMPANY NAME: Real Research

WEBSITE : <https://www.real-research.com>

YEAR OF ESTABLISHMENT: 2017

NUMBER OF EMPLOYEES: 9

CERTIFICATIONS: LifeGel® patent.

PRODUCTS: Products: LifeGel® for 3D cell culture; LifeGel® for spheroidal growth of mesenchymal stem cells; LifeGel® starter pack; digestion kit; Tissue digestion kit. Services: 3D cell culture; drug screening on 3D cell culture; primary tumor tissue drug screening; pharmacokinetics research on LifeCube; single cell cloning.

FORM OF COOPERATION: Trade and distribution, Investment



Real Research is a leader in 3D cell culture (3DCC) tools and services. Our main product: hydrogel LifeGel® can be customized to specific needs. Thus we are creating a huge innovative technological platform that we can modify to get the right background for any type of cell and customized it for tumor models. We are looking for: 1) pharma to work together on drug discovery and preclinical trials, especially in oncology, 2) investors to join our seed and A rounds. We are collaborating with academia, pharma, and biotech companies: UJ, UG, NIO, IMol, Xentech, BioXplor, Targa Biomedical, Revatis, cell2in, Seed Therapeutics.



Polish Biotechnology Sector

COMPANY NAME: Ryvu Therapeutics

WEBSITE : <https://www.ryvu.com/>

YEAR OF ESTABLISHMENT: 2007

NUMBER OF EMPLOYEES: 230

CERTIFICATIONS: -

PRODUCTS: Ryvu pipeline comprises a range of promising candidates with unique properties derived from various programs, including kinase inhibitors, synthetic lethality, and immuno-oncology

FORM OF COOPERATION: Investment



Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel small-molecule therapies that address emerging targets in oncology. Ryvu's most advanced programs are RVU120 — a selective CDK8/CDK19 kinase inhibitor with potential for the treatment of hematological malignancies and solid tumors currently in phase I clinical development for the treatment of AML and HR-MDS, and phase I/II for the treatment of r/r metastatic or advanced solid tumors — and SEL24 (MEN1703), a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group, currently in phase II clinical studies in AML.



Polish Biotechnology Sector

COMPANY NAME: Sano Centre for Computational Medicine - International Research Institute - Centre of Excellence

WEBSITE : <https://www.sano.science>

YEAR OF ESTABLISHMENT: 2019

NUMBER OF EMPLOYEES: 92

CERTIFICATIONS: -



PRODUCTS: Health Informatics; Personal Health Data Science; Extreme-scale Data and Computing; Computer Vision; Digital Therapeutics; Clinical Decision Support Systems; Research and Collaboration

FORM OF COOPERATION: Joint Venture, Investment



At Sano, we create solutions for hospitals, doctors, and the MedTech industry. We had partnerships with many institutions in the USA, UK, Italy, Germany, Portugal, Netherlands, Romania, Belgium, and Poland of course. We are dedicated to driving the widespread adoption of digital health innovations in critical areas of healthcare. To achieve this goal, we conduct thorough research to develop innovative co-created frameworks that can enhance the quality and effectiveness of health services. Our focus on investigating and designing implementation methods ensures that the incorporation of health innovations into routine practices are facilitated and well-managed.

Polish Biotechnology Sector

COMPANY NAME: SDS Optic Inc.

WEBSITE : <https://www.sdsoptic.com/>

YEAR OF ESTABLISHMENT: 2013

NUMBER OF EMPLOYEES: 40

CERTIFICATIONS: ISO 13485:2016, we are running clinical trials and moving towards EU-MDR certification.



PRODUCTS: inPROBE is a micron-size single-cell resolution fibre optic microprobe for HER2+ breast cancer real-time diagnostics. The tip of the probe, covered with biological compounds, enables sensing specific cancer biomarkers in real-time, in vivo (no tissue biopsy).

FORM OF COOPERATION: Trade and distribution, Joint Venture



We have developed inPROBE, a disruptive bio-photonics device for breast cancer diagnostic and targeted therapeutics development and delivery monitoring as a future scale up. Designed to be used by physicians in various medical settings such as clinics, hospitals, and laboratories. We are currently seeking to expand our network of contacts in the biotech and medtech industry, including distributors and retailers. Our commercialization strategy involves establishing a corporate partnership with a major global biotech/medtech corporation, and we are interested in meeting with well-known international brands in the market to showcase our technology and explore potential collaborations.

COMPANY NAME: Selvita S.A.



WEBSITE : <https://www.selvita.com>


YEAR OF ESTABLISHMENT: 2007

NUMBER OF EMPLOYEES: 900

CERTIFICATIONS: GLP; AALAC; GMP

PRODUCTS: Selvita is an integrated service provider aiming to deliver a set of comprehensive solutions supporting customers and projects within area of drug discovery and drug development.

FORM OF COOPERATION: Joint Venture



Selvita is one of the largest preclinical contract research organizations in Europe, driven by a clear mission: to offer a comprehensive scope of services bridging the gap between early drug discovery and the clinical stage of drug development. Selvita provides comprehensive solutions across a broad range of therapeutic areas, specializing in infectious diseases, inflammation, fibrosis, and oncology. The Company offers a range of stand-alone or fully integrated drug discovery and development solutions spanning the entire value chain from early drug discovery to preclinical development. On top of that Selvita also offers analytical support of drug development and contract testing studies.

COMPANY NAME: Solution4Labs



WEBSITE : <https://www.solution4labs.com/en/>

YEAR OF ESTABLISHMENT: 2014

NUMBER OF EMPLOYEES: 30

CERTIFICATIONS: ISO 9001; ISO 27001

PRODUCTS: Lab informatics, Instruments integration, Digital Audit, Integration between different Lab systems, Digital Consultancy, pre-LIMS Analysis, Project Management / Product Owning - for LIMS implementations

FORM OF COOPERATION: Trade and distribution



Solution4Labs offers innovative solutions for every company that has a testing lab. Our lab digitalization services have been successfully implemented in over 50 different projects for clients all around the globe, with the majority of them in Poland, France, UK, Japan. We've worked with clients on the Fortune 500 list. With our expertise in laboratory equipment, supplies, and services, we can help your company improve efficiency, accuracy, and safety in your testing lab. Contact us to learn more about how we can help your business grow.

Polish Biotechnology Sector

COMPANY NAME: Syvento sp. z o.o.

WEBSITE : <https://www.biotech.syvento.com>

YEAR OF ESTABLISHMENT: 2015

NUMBER OF EMPLOYEES: 50

CERTIFICATIONS:

PRODUCTS: - Synthesis of ribonucleic acids - Development of LNP and liposomal formulations - Production of developed LNP/liposomal batches for all clinical trial phases - Expert services at all levels of product development

FORM OF COOPERATION: Trade and distribution

syvento | **BIO
TECH**



SyVento BioTech is a biotechnology company offering comprehensive services in the development of lipid-based nanocarriers and LNP technology. We specialize in the development of lipid-based formulations for pharmaceutical products, including RNA-based drug products. Our unique in a global scale end-to-end service gives the opportunity to design and implement projects to encapsulate and deliver therapeutic molecules such as small molecules, RNA, DNA, and proteins to targeted cells or tissues. Our expertise includes the development of liposomal formulations, RNA synthesis and production (F&F), along with support services at all levels of product development.

Polish Biotechnology Sector

COMPANY NAME: WPD Pharmaceuticals sp. z o.o.

WEBSITE : <https://www.wpdpharmaceuticals.com>



YEAR OF ESTABLISHMENT: 2017

NUMBER OF EMPLOYEES: 15

CERTIFICATIONS: -

PRODUCTS: WPD's has two highly promising biological drug candidates at the pre-clinical stage: WPD101a; WPD103; and clinical stage drug candidate: Berubicin. WPD offers licensing-out, co-development and consulting services in clinical trials in oncology drug development with focus on glioblastoma.

FORM OF COOPERATION: Joint Venture, Investment



WPD Pharmaceuticals focuses on developing biological and chemical molecules involved in targeted therapy for brain gliomas and other central nervous system cancers. WPD has exclusive rights (worldwide or for specific territories) for several novel drug candidates in either preclinical and clinical stage development. WPD is well prepared and organized to create and implement clinical development strategies, including interaction with the EMA and other regulatory bodies, as well as CRO and programs supervision. In addition to developing in-house and co-development programs, WPD can provide these services commercially to US and EU companies.

PAIH for polish biotechnology

We are committed to promoting Poland and the Polish economy. We aim to increase the awareness of Polish brands on international markets. We promote National products and services, as well as Polish innovative Information technology. We help entrepreneurs select their optimal foreign expansion path.

PAIH's Offer for Exporters:

- Analysis of export potential
- Preparing and verifying lists of possible potential partners
- Developing strategies for expansion in selected markets
- Organizing B2B meetings
- Organizing business missions

Check what else we have on offer on www.paih.gov.pl